(Q37311579)

English

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

scientific article published on 04 October 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Yongkun Sun

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Wei Niu

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Feng Du

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Chunxia Du

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Shuting Li

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jinwan Wang

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Li Li

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Fengqing Wang

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Yu Hao

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Chuan Li

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Yihebali Chi

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

4 October 2016

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Hematology & Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

105

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

https://scigraph.springernature.com/pub.10.1186/s13045-016-0332-8

0 references

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Development and strategies of VEGFR-2/KDR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

FGFR2 gene amplification and clinicopathological features in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Fibroblast growth factors and their receptors in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Hallmarks of Cancer: The Next Generation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Fibroblast growth factor signalling: from development to cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

De-regulated FGF receptors as therapeutic targets in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

6 September 2017

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

14 September 2017

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

14 September 2017

Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

2 September 2018

Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5051080

2 September 2018

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/27716285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13045-016-0332-8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37311579&oldid=1543944483"